AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03046069 — intervention group
Intervention type: OTHER
Intervention: Online DCE survey
Description: An online DCE survey questionnaire will be given to the subjects to identify subject preferences, priorities and treatment goals.
Study NCT02014285 — intervention group
Intervention type: PROCEDURE
Intervention: Muscle Ultrasound and Muscle Sample
Description: The muscles to undergo ultrasound will include the biceps brachii, wrist extensors, quadriceps, and tibialis anterior. A muscle sample will be taken from the rectus femoris.
Study NCT03128346 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: IV, fentanyl
Study NCT03193931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab Injection
Description: Pembrolizumab 200 mg q3w i.v. until disease progression or non-tolerable toxicity (maximum 2 years)
Study NCT03193931 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate Injectable Solution
Description: Methotrexate 40 mg/m2 weekly i.v. until disease progression or non-tolerable toxicity (maximum 2 years)
Study NCT01662518 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dexamethasone drug delivery system (DDS-25)
Description: 350 mg Dexamethasone posterior segment drug delivery system (DDS-25) injection into the vitreous cavity at baseline
Study NCT03318250 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dorsal Root Ganglion Stimulation
Description: During the Dorsal Root Ganglion implant , SCS leads will be implanted using a TransGrade Dorsal Root Ganglion Technique. Antibiotic prophylaxis is performed prior to surgery for both trial and permanent implant phase. Using the technique lead placement will be performed through a small skin incision under local anaesthesia supplemented by conscious sedation. The leads will be placed along the DRG to obtain stimulation coverage over as much of the pain area as possible. After the leads have been implanted, x-ray or fluoroscopy images will be taken to record the final lead locations. Once intervention is completed participants will assigned either DRG-LF and Burst3D device programme.
Study NCT01127412 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical activity stimulating program
Study NCT00878527 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CircuLite Synergy Pocket Circulatory Assist Device
Description: Goal of successful implantation and follow-up for at least three months
Study NCT02977988 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Meditation
Description: MBRP-W is delivered in 12 bi-weekly 80-minute group sessions. Facilitators with previous experience in MBSR and trained in MBRP-W will deliver each group. Each session has a central theme and is divided into five segments consisting of: (a) a welcome meditation or other mindfulness practice, (b) a review of session objectives, (c) a brief didactic psycho-educational presentation and discussion based on the session's theme, (d) experiential and formal meditation or other practices, and (e) readings and assignments for the next class. Participants are expected to learn skill building techniques to reducing stress using mindfulness-based principles to complement their recovery treatment program.
Study NCT02977988 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brain and Recovery (B&R)
Description: B\&R is delivered in 12 bi-weekly 80-minute group sessions delivered by two trained interventionists. The B\&R group will receive didactic education on the neurobiology of addiction. B\&R contains no information on behavior change, stress reduction, or mindfulness-based or relapse-related content. The intervention was developed over three years with a population similar to those in the study and with input from patients and experts on neurobiology of addiction. Topics include: (1) brain structures and functions related to addiction, (2) effects of various types of substances on the brain, and (3) rewarding effects and how these lead to addiction. Participants are expected to gain knowledge pertaining to the effects of drugs on the brain.
Study NCT00674661 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: riboflavin ophthalmic solution
Description: riboflavin 0.1% ophthalmic solution (approximately 32 drops, or 1.6 mL)
Study NCT00674661 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: riboflavin ophthalmic solution
Description: riboflavin 0.1% ophthalmic solution (approximately 32 drops, or 1.6 mL)
Study NCT00674661 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: UVA Irradiation
Description: UVA light (365 nm at an irradiance of 3 mW/cm2) for 30 minutes
Study NCT02432534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: The patients will be treated with the combination of oral atorvastatin and NBUVB phototherapy twice a week for 6 months. The initial starting dose of the oral atorvastatin will be 40mg daily and after 1 month, if tolerated clinically and biologically following blood tests, the dose will be increased to 80mg daily.
Study NCT02432534 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: UVB
Description: The patients will be receiving only NB-UVB phototherapy twice a week for 6 months.
Study NCT03016286 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: vibration
Description: Whole body vibration at 25Hz frequency
Study NCT01968668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY94-8862
Description: 1.25 mg BAY94-8862 tablet once daily in the morning
Study NCT01968668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY94-8862
Description: 2.5 mg BAY94-8862 tablet once daily in the morning
Study NCT01968668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY94-8862
Description: 5 mg BAY94-8862 tablet once daily in the morning
Study NCT01968668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY94-8862
Description: 7.5 mg BAY94-8862 tablet once daily in the morning
Study NCT01968668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY94-8862
Description: 10 mg BAY94-8862 tablet once daily in the morning
Study NCT01968668 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet once daily in the morning
Study NCT01968668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY 94-8862
Description: 15 mg BAY 94-8862 tablet once daily in the morning
Study NCT01968668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY 94-8862
Description: 20 mg BAY 94-8862 tablet once daily in the morning
Study NCT01053819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etanercept
Description: Patients will receive six months of treatment with Enbrel 50mg SQ given twice a week for the first three months and 50 mg once a week thereafter.
Study NCT01552252 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: apple juice
Description: unaltered(0% POs-Ca) commercially available apple juice
Study NCT01552252 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: apple juice with 0.5% POs-Ca
Description: Phosphoryl Oligosaccharides of Calcium (POs-Ca) in the form of powder was added at concentrations of 0.5% by weight to a commercially available apple juice
Study NCT01552252 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: apple juice with 1% POs-Ca
Description: Phosphoryl Oligosaccharides of Calcium (POs-Ca) in the form of powder was added at concentrations of 1% by weight to a commercially available apple juice
Study NCT01552252 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: apple juice with 1.5% POs-Ca
Description: Phosphoryl Oligosaccharides of Calcium (POs-Ca) in the form of powder was added at concentrations of 1.5% by weight to a commercially available apple juice
Study NCT01552252 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: apple juice with 2% POs-Ca
Description: Phosphoryl Oligosaccharides of Calcium (POs-Ca) in the form of powder was added at concentrations of 2% by weight to a commercially available apple juice
Study NCT00276159 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 852A
Description: Subcutaneous injection 0.6 mg/m2 2 times/week/12 weeks, may increase by 0.2 mg/m2 up to 1.2 mg/m2.
Study NCT00946959 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cardiac surgery
Description: A study-certified cardiothoracic surgeon must deem a patient, who otherwise fulfills all inclusion and exclusion criteria for any cardiac surgery (conventional, off-pump cardiac surgery). The procedure must be performed as soon as possible.
Study NCT01477840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: Sublingual Misoprostol 200 Micrograms After Spinal Anesthesia
Study NCT03762109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dantrolene
Description: muscle relaxant
Study NCT03762109 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: inactive pill
Study NCT03012347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY987517
Description: Subjects will be instructed to apply the test article in a split-body and face configuration, to the assigned side of the body (face, arms, torso, and legs), as they normally would before going outdoors for a run, walk or other sport related activity. (Formulation: RB# Y73-161)
Study NCT03012347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BullFrog Gel Sunscreen Land Sport SPF-50
Description: Subjects will be instructed to apply the test article in a split-body and face configuration, to the assigned side of the body (face, arms, torso, and legs), as they normally would before going outdoors for a run, walk or other sport related activity.
Study NCT02426892 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ISA 101
Description: 100 mcg administered subcutaneously for a total of 3 doses at 3 to 4 weeks intervals starting on Day 1.
Study NCT02426892 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 3 mg/kg administered by vein every 2 weeks beginning on Day 8 after the first vaccine dose.
Study NCT02053467 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Champlain BASE eConsult Service
Description: After undergoing registration, which includes orientation and brief training on the use of the service, physicians randomized to intervention arm will be able to submit patient-specific clinical questions to specialists through a secure, web-based application. Specialists are asked to respond within 7 days and, for each eConsult, are able to: (1) provide a recommendation, (2) request more information, or (3) recommend a face-to-face referral. The communication between PCPs and specialists is iterative and the discussion can occur back and forth until, ultimately, the PCP closes the case.
Study NCT01832870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sipuleucel-T
Study NCT01832870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ipilimumab
Study NCT01035203 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Endurance exercise 3 times weekly for 45 minutes, 4 weeks long
Study NCT01035203 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive behavioural therapy
Description: Teaching of techniques to reduce fatigue and to improve stamina
Study NCT00487851 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgery
Description: hepaticojejunostomy and gastroenterostomy
Study NCT00487851 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: endoscopic strategy
Description: Stent insertion
Study NCT03178773 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TExT-MED
Description: messages designed to inspire motivation and behavior change
Study NCT03178773 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TExT-MED
Description: messages designed to inspire motivation and behavior change
Study NCT03178773 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FANS
Description: SMS delivered messages to family members to improve social support
Study NCT00356369 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: meningococcal ACWY (vaccine)
Description: One intramuscular dose.
Study NCT00356369 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Mencevax™ ACWY
Description: One subcutaneous dose.
Study NCT03184415 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DWC20155
Description: tablet
Study NCT00240565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tositumomab 450 mg
Description: Unlabeled TST
Study NCT03184415 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWC20155
Description: tablet
Study NCT03184415 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWC20156
Description: tablet
Study NCT03184415 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DWC20156
Description: tablet
Study NCT03184415 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo of DWC20155
Description: tablet
Study NCT03184415 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo of DWC20155
Description: tablet
Study NCT00240565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tositumomab 35 mg
Description: TST labeled with 185 megaBecqueral (mbq) of iodine 131
Study NCT04108715 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector spina plain block for mastectomy analgesia
Description: After giving general anesthesia, patient is positioned in lateral decubitus with the surgical side up, An erector Spina plain block is performed with inserting block needle (Pajunk, Geisingen, Germany) in-plane under ultrasound control until needle tip hits the transverse process, a volume of 0.3 ml/kg of bupivacaine 0.25% (Marcaine, Astra Zeneca Pharmaceuticals) is injected. Pain management assessment and analgesic consumption will be provided through patient-controlled analgesia (PCA) for 24 hours. The PCA pump is programmed to deliver 1 mg morphine bolus per press with a lockout interval of 10 min. Pain scores will be measured using eleven points numerical rating scale NRS (0 to 10) and opioids consumption will be documented at 0, 1, 4, 8 and 24 hours. Time of admission to post-anesthesia care unit PACU is considered 0 hours. Any opioid equivalents given during the first 24 hours to manage breakthrough pain will be documented
Study NCT03184415 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo of DWC20156
Description: tablet
Study NCT01271660 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Description: drug form : capsule, 75/150mg. Pregabalin will be provided to treatment arm subjects for 6-week Treatment period.~Treatment period : 75 mg twice daily during the first 1 week as titration + 150mg twice daily for 4 weeks as maintenance + 75mg twice a day as tapering
Study NCT01271660 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: drug form : capsule, 75/150mg. Pregabalin will be provided to treatment arm subjects for 6-week Treatment period.~Treatment period : 75 mg twice daily during the first 1 week as titration + 150mg twice daily for 4 weeks as maintenance + 75mg twice a day as tapering
Study NCT06231212 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ECa 233
Description: Intervention groups are separated into group A and group B. Group A takes capsules containing 250 mg of ECa 233 and group B takes capsules containing 500 mg of ECa 233.
Study NCT06231212 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: Ibuprofen group was given capsules containing 200 mg of ibuprofen
Study NCT06231212 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo-controlled group received capsules containing 250 mg of lactose
Study NCT01876342 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: open repair
Description: 2-0 sutures
Study NCT01876342 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: endoscopic TEP repair
Description: mesh
Study NCT04034381 — intervention group
Intervention type: OTHER
Intervention: No intervention (descriptive survey only)
Description: No intervention
Study NCT04108715 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Deep serratus anterior plane block
Description: After giving general anesthesia, the patient is positioned in lateral decubitus, with the surgical side up. The upper arm is abducted and elevated above the head level. A block needle is introduced in-plane, targeting the plane deep to the serratus anterior muscle, and a bolus of 0.3 ml/kg bupivacaine 0.25% is injected through ultrasound guidance. Pain management assessment and analgesic consumption will be provided through patient-controlled analgesia PCA for 24 hours. The PCA pump is programmed to deliver 1 mg morphine bolus per press with a lockout interval of 10 min. Pain scores will be measured using eleven points numerical rating scale NRS (0 to 10), and opioids consumption will be documented at 0, 1, 4, 8 and 24 hours. Time of admission to PACU is considered 0 hours. Any opioid equivalents given during the first 24 hours to manage breakthrough pain will be documented
Study NCT03671408 — intervention group
Intervention type: OTHER
Intervention: clinical measurements
Description: only clinical parameters were recorded
Study NCT01811602 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Training
Description: The participants randomized to the pelvic floor muscle training intervention will receive pelvic floor muscle training (0-12 weeks) delivered by a physiotherapist with clinical expertise and training in treating pelvic floor dysfunction. The intervention is 9 individual, one-on-one, 45-minute sessions; weekly for weeks 0-6 and bi-weekly for weeks 7-12 (first session will be 60 minutes). The sessions will provide pelvic floor muscle training based on the latest evidence, including biofeedback, to teach the correct technique for pelvic floor contractions, and participants will be asked to complete daily pelvic floor exercises at home.
Study NCT01811602 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: The participants randomized to the educational pamphlet intervention (usual care control) will receive a 1-page sheet on pelvic floor muscle training, specifically Kegel exercises, which is equivalent to current standard care. Individuals randomized to this group will be placed on the clinic waiting list and be eligible for treatment following completion of the 12 week (end of study) measures.
Study NCT00926133 — intervention group
Intervention type: OTHER
Intervention: OGTT
Description: Oral glucose tolerance test (diagnostic procedure) eary after an acute STEMI and at three months follow-up.
Study NCT02557113 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vertebroplasty
Description: Fractured Osteoporotic Vertebral Body is Augmented with Injection of Bone Cement
Study NCT02557113 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cavuplasty
Description: Small Cavity is Created in Fractured Osteoporotic Vertebral Body Prior to Cement Injection
Study NCT01752400 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AUY922
Study NCT01974752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 75mg selumetinib
Description: selumetinib tablets p.o. twice daily taken in combination with dacarbazine 1000mg/m2 iv on day 1 of every 21-day cycle.
Study NCT01974752 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo tablets p.o. twice daily taken in combination with dacarbazine 1000mg/m2 iv on day 1 of every 21-day cycle.
Study NCT01974752 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dacarbazine
Description: dacarbazine 1000mg/m2 iv on day 1 of every 21-day cycle taken in combination with either selumetinib or placebo tablets p.o. twice daily.
Study NCT01974752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacarbazine
Description: dacarbazine 1000mg/m2 iv on day 1 of every 21-day cycle taken in combination with either selumetinib or placebo tablets p.o. twice daily.
Study NCT01766895 — intervention group
Intervention type: OTHER
Intervention: blood sampling
Description: blood sampling of viral hepatitis to determined seroprevalence in uremic patients
Study NCT00393302 — intervention group
Intervention type: PROCEDURE
Intervention: HIV screening in pregnancy
Study NCT02010736 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Single treadmill gait training with additional loading
Study NCT01369082 — intervention group
Intervention type: DRUG
Intervention: Maintenance Immunosuppressive Treatment
Description: All immunosuppressive and immunomodulatory therapies are used presently to prevent rejection of transplanted islet cells. The agents listed are those used in the parent trials and continued in this trial, CIT08.
Study NCT01741831 — intervention group
Intervention type: DRUG
Intervention: No intervention
Description: This is an observational study. Darunavir will be administered as per the recommended doses and will be given orally for a period of 24 weeks. For treatment naive (never received treatment for AIDS) patients: Darunavir 800 mg will be adminstered along with ritonavir 100 mg once daily. For experienced patients: Darunavir 600 mg will be administered along with ritonavir 100 mg twice daily.
Study NCT04096781 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SDMT
Description: The intervention involves a clear pathway centered on the use of a web-based decision tool. This tool aims to support the shared decision-making process for anticoagulation for stroke prevention in atrial fibrillation. This web-based tool will be used both by the participants as well the physician responsible for atrial fibrillation decision making.